These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 21125406

  • 1. Additive effect of PPAR-γ agonist and ARB in treatment of experimental IgA nephropathy.
    Lai KN, Chan LY, Guo H, Tang SC, Leung JC.
    Pediatr Nephrol; 2011 Feb; 26(2):257-66. PubMed ID: 21125406
    [Abstract] [Full Text] [Related]

  • 2. Crosstalk between peroxisome proliferator-activated receptor-gamma and angiotensin II in renal tubular epithelial cells in IgA nephropathy.
    Xiao J, Leung JC, Chan LY, Tang SC, Lai KN.
    Clin Immunol; 2009 Aug; 132(2):266-76. PubMed ID: 19443277
    [Abstract] [Full Text] [Related]

  • 3. Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy.
    Xiao J, Leung JC, Chan LY, Guo H, Lai KN.
    Nephrol Dial Transplant; 2009 Jul; 24(7):2067-77. PubMed ID: 19155534
    [Abstract] [Full Text] [Related]

  • 4. The study of Chinese medicinal herbal formula Shen San Fang in the treatment of experimental IgA nephropathy.
    Zhong Q, Leung JC, Chan LY, Tsang AW, Chen X, Lai KN.
    Am J Chin Med; 2005 Jul; 33(4):613-26. PubMed ID: 16173535
    [Abstract] [Full Text] [Related]

  • 5. Advanced IgA nephropathy with impaired renal function benefits from losartan treatment in rats.
    Wang H, Fu W, Jin Z, Wang Y, Yao W, Yin P, Peng W.
    Ren Fail; 2013 Jul; 35(6):812-8. PubMed ID: 23751143
    [Abstract] [Full Text] [Related]

  • 6. Toll-like Receptor 4 Signaling Pathway in the Protective Effect of Pioglitazone on Experimental Immunoglobulin A Nephropathy.
    Zou JN, Xiao J, Hu SS, Fu CS, Zhang XL, Zhang ZX, Lu YJ, Chen WJ, Ye ZB.
    Chin Med J (Engl); 2017 Apr 20; 130(8):906-913. PubMed ID: 28397719
    [Abstract] [Full Text] [Related]

  • 7. Vitamin E ameliorates renal injury in an experimental model of immunoglobulin A nephropathy.
    Trachtman H, Chan JC, Chan W, Valderrama E, Brandt R, Wakely P, Futterweit S, Maesaka J, Ma C.
    Pediatr Res; 1996 Oct 20; 40(4):620-6. PubMed ID: 8888293
    [Abstract] [Full Text] [Related]

  • 8. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
    Erman A, Veksler S, Gafter U, Boner G, Wittenberg C, van Dijk DJ.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep 20; 5(3):146-51. PubMed ID: 15526251
    [Abstract] [Full Text] [Related]

  • 9. Huangqi Guizhi Wuwu Decoction attenuates Podocyte cytoskeletal protein damage in IgA nephropathy rats by regulating AT1R/Nephrin/c-Abl pathway.
    Liu W, Shi L, Wan Q, Wu Y, Huang D, Ou J, Liu Q, Guan X, Yang Y, Zhang X, Gao J.
    Biomed Pharmacother; 2021 Oct 20; 142():111907. PubMed ID: 34339916
    [Abstract] [Full Text] [Related]

  • 10. Effects of therapeutic agents on the inflammatory and fibrogenic factors in IgA nephropathy.
    Ihm CG, Jeong KW, Lee SH, Lee TW, Park JK.
    Nephrology (Carlton); 2007 Dec 20; 12 Suppl 3():S25-6. PubMed ID: 17995524
    [Abstract] [Full Text] [Related]

  • 11. Tubular expression of angiotensin II receptors and their regulation in IgA nephropathy.
    Chan LY, Leung JC, Tang SC, Choy CB, Lai KN.
    J Am Soc Nephrol; 2005 Aug 20; 16(8):2306-17. PubMed ID: 15930094
    [Abstract] [Full Text] [Related]

  • 12. Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy.
    Nagasawa H, Ueda S, Suzuki H, Jenkinson C, Fukao Y, Nakayama M, Otsuka T, Okuma T, Clapper W, Liu K, Nguyen M, Komers R, Suzuki Y.
    Nephrol Dial Transplant; 2024 Aug 30; 39(9):1494-1503. PubMed ID: 38271614
    [Abstract] [Full Text] [Related]

  • 13. Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy.
    Kim HJ, Ryu JH, Han SW, Park IK, Paik SS, Park MH, Paik DJ, Chung HS, Kim SW, Lee JU.
    Nephron Physiol; 2004 Aug 30; 97(4):p58-65. PubMed ID: 15331931
    [Abstract] [Full Text] [Related]

  • 14. Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.
    Yamamoto S, Zhong J, Yancey PG, Zuo Y, Linton MF, Fazio S, Yang H, Narita I, Kon V.
    Atherosclerosis; 2015 Sep 30; 242(1):56-64. PubMed ID: 26184694
    [Abstract] [Full Text] [Related]

  • 15. Hirudin ameliorates immunoglobulin A nephropathy by inhibition of fibrosis and inflammatory response.
    Deng F, Zhang J, Li Y, Wang W, Hong D, Li G, Feng J.
    Ren Fail; 2019 Nov 30; 41(1):104-112. PubMed ID: 30880546
    [Abstract] [Full Text] [Related]

  • 16. Oxidative damages in tubular epithelial cells in IgA nephropathy: role of crosstalk between angiotensin II and aldosterone.
    Leung JC, Chan LY, Tang SC, Lam MF, Chow CW, Lim AI, Lai KN.
    J Transl Med; 2011 Oct 06; 9():169. PubMed ID: 21974877
    [Abstract] [Full Text] [Related]

  • 17. Anti-macrophage migration inhibitory factor reduces transforming growth factor-beta 1 expression in experimental IgA nephropathy.
    Leung JC, Chan LY, Tsang AW, Liu EW, Lam MF, Tang SC, Lai KN.
    Nephrol Dial Transplant; 2004 Aug 06; 19(8):1976-85. PubMed ID: 15187193
    [Abstract] [Full Text] [Related]

  • 18. [Effect of telmisartan on tubulointerstitial injury and expression of PPARγ in rat renal tissue of IgA nephropathy model].
    Xing L, Bai L, Yu CY, Xie RJ.
    Zhonghua Yi Xue Za Zhi; 2010 Nov 02; 90(40):2860-3. PubMed ID: 21162800
    [Abstract] [Full Text] [Related]

  • 19. Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial.
    Li P, Chen YZ, Lin HL, Ni ZH, Zhan YL, Wang R, Yang HT, Fang JA, Wang NS, Li WG, Sun XF, Chen XM.
    Trials; 2017 Apr 11; 18(1):170. PubMed ID: 28395659
    [Abstract] [Full Text] [Related]

  • 20. Effects of combination PPARγ agonist and angiotensin receptor blocker on glomerulosclerosis.
    Matsushita K, Yang HC, Mysore MM, Zhong J, Shyr Y, Ma LJ, Fogo AB.
    Lab Invest; 2016 Jun 11; 96(6):602-9. PubMed ID: 26999660
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.